Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
A Phase I, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
Sponsor: Biogen
Terminated
A company's strategic decision to focus on areas whereit believes it can be competitive and decided to exit Oncology
Listed as NCT00651443, this PHASE1 trial focuses on Lymphoma, Non-Hodgkin's and remains terminated or withdrawn. Sponsored by Biogen, it has been updated 10 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .